Following approval in November from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), Nanomerics Ltd., a private speciality pharmaceutical company, and Quotient Sciences have commenced dosing the first volunteers for the Phase I trial of OC134.
OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist.
The clinical testing of Nanomerics’ eye drop assets is being done by Quotient Sciences - Nottingham, UK.
Dr Nand Singh, Medical Director at Quotiexnt Sciences commented, “We are excited to begin clinical testing at our Nottingham, UK clinic for Nanomerics’ OC134 Phase 1 Sunlight trial. This marks an important step forward in developing advanced treatments for moderate to severe conjunctivitis.”
Continue reading the announcement from Nanomerics